For UK clinics and healthcare providers
You have a treatment or service ready to promote but no structured patient or referrer acquisition strategy
Launching a new treatment without a structured acquisition strategy means relying on word of mouth and existing patient flow, which rarely generates enough volume fast enough to make the service commercially viable. The cost of a slow launch compounds every month the pathway runs below capacity.
Cost of Inaction
Enter your monthly website visitors, your current and achievable enquiry rate, and average patient value. The calculator shows the annual value of the enquiries a slow launch is costing you.
How it breaks down
- Current annual patient value£13,548
- Target annual patient value£31,611
Two minutes, no typing, and I read every one myself.
From Paul
Tell me where that £18,063 is coming from, and I'll come back with the three things to fix first.
A few quick questions, about two minutes, and no typing. I read every one myself and reply with the three things costing you most and where I'd start. If it's useful, we talk. If not, you've still got a clear picture.
No obligation, no sales call unless you ask for one, and nothing automated lands in your inbox.
Paul, Solvable
- Pathway launched but referral volumes are low
- GPs and consultants in the area don't know the treatment is available
- No website page or patient information about the treatment
- Enquiries come in but conversion process is unclear
- pathway runs below capacity, fixed costs not covered
- clinical team capacity underutilised
- treatment exists but has no market awareness
Frequently asked questions
Why does this problem persist?
Clinical teams focus on getting the treatment ready. Commercial planning is treated as something to do after launch rather than before. By the time the pathway is live, there's no referrer awareness, no patient-facing content, and no channel driving enquiries.
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.